* Microbot Medical Inc MBOT.OQ MBOT.O is expected
to report
results on August 15 (estimated).
* Refinitiv's mean analyst estimate for Microbot Medical
Inc is
for a loss of 45 cents per share. For the same quarter last
year, the company reported a loss of 35 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Microbot
Medical
Inc is $20, above its last closing price of $5.25.
This summary was machine generated August 12 at 12:00 GMT. All
figures in US dollars unless otherwise stated